# Diabetes Research Hub — Monitor Report
**Run date:** 2026-06-16 (automated, unattended)
**Scope:** Reviewed latest script outputs in `Analysis/Results/`, compared snapshots, ran web check. No files modified.

---

## Headline (most actionable)

**FDA approved Tzield (teplizumab) for pediatric Stage 3 T1D on 2026-06-12** — the first disease-modifying therapy for *recently diagnosed* Stage 3 type 1 diabetes (ages 8–17), via accelerated approval on a C-peptide surrogate endpoint. This is directly relevant to the hub: we track ≥6 teplizumab trials and the T1D Immunotherapy domain. **Action: update the tracker and teplizumab trial records.** [Evidence: GOLD — FDA + sponsor primary sources.]

---

## File System Status

| File | Last modified | Freshness | Note |
|------|---------------|-----------|------|
| `clinical_trials_latest.json` | 2026-06-15 | Current (1 day) | 809 trials |
| `hub_monitor_report.md` | 2026-06-15 | Current | 3 new / 27 modified files |
| `pubmed_recent_latest.json` | 2026-06-12 | **Stale (4 days)** | Refresh recommended |
| `literature_gap_report.md` | 2026-06-14 | Current (2 days) | Human-readable |
| `literature_gap_data.json` | 2026-04-20 | **STALE (~57 days)** | Underlying data far older than the report it feeds |

**Flag:** The gap *report* (Jun 14) and the gap *data JSON* (Apr 20) are 55 days apart. The report's numbers rest on April data. Treat gap rankings as provisional until `project1_literature_gap_analysis.py` is re-run. The hub_monitor itself flagged 716 result files older than 14 days.

---

## Clinical Trial Changes (vs. 2026-06-09 snapshot)

- **Total trials:** 809 (was 806) — **+6 new, −3 removed, 0 status changes, 0 new results posted.**
- The 6 new trials are all `NOT_YET_RECRUITING`, device/neuromodulation/CGM-accuracy studies (Insulet, Steno, Yuwell, Boston Scientific ESG, vagus-nerve stimulation). None are high-priority therapeutics. [Evidence: SILVER — snapshot diff.]

**Phase 3 RECRUITING:** 46 trials. Key ones aligned with our priority therapies:

| NCT | Sponsor | Therapy | Status | Why it matters |
|-----|---------|---------|--------|----------------|
| NCT04786262 | Vertex | VX-880 (zimislecel) | RECRUITING P3 | Lead stem-cell islet cure for T1D |
| NCT06832410 | Vertex | VX-880 | RECRUITING P3 | Second pivotal VX-880 study |
| NCT07222332 | Eli Lilly | Baricitinib | RECRUITING P3 | JAK inhibitor to *preserve* beta cell function in new-onset T1D |
| NCT07222137 | Eli Lilly | Baricitinib | RECRUITING P3 | Baricitinib to delay Stage 3 T1D |
| NCT07088068 | — | Teplizumab | RECRUITING P3 | Now de-risked by the 6/12 FDA pediatric approval |
| NCT07564414 | Novo Nordisk | CagriSema | RECRUITING P3 | Dose-comparison |
| NCT07076199 | Novo Nordisk | Insulin icodec | RECRUITING P3 | Weekly insulin |

VX-264 (NCT05791201, Vertex encapsulated islets) remains `ACTIVE_NOT_RECRUITING` Phase 1/2 — watch for a readout. No new results were posted on any tracked trial this cycle.

---

## PubMed Highlights (pubmed_recent_latest.json, 165 papers; data through 6/12)

**Cross-domain papers (highest value — 13 total).** Standouts:

- **[42259339]** *Orforglipron compared with dapagliflozin in T2D* — **Lancet**, Jun 8. Oral GLP-1 head-to-head vs. SGLT2. (Key Therapy ×2)
- **[42198313]** *Diabetes Mellitus and Stroke* — links **retatrutide + CagriSema** therapeutic angles. May 19.
- **[42277427]** *Lentiviral GLP-1 gene therapy → β-cell regeneration in diabetic models* — J Mol Med, Jun 12. (T2D GLP-1 × Gene Therapy)
- **[42267680]** *Early teplizumab response via CGM* — Diabetes Tech & Ther, Jun 10. (T1D Immunotherapy × teplizumab) — timely given the FDA action.
- **[42268809] / [42270051]** Two microbiome × biomarker papers (pregnancy complications; L. casei cognition in T2DM).

**Key-therapy publication clusters** (signal of an ADA-2026 / journal wave):
- **Orforglipron — 4 papers** (Lancet + 3× JAMA, incl. ACHIEVE-add-on-to-glargine).
- **CagriSema — 4 papers** (Lancet Diab-Endo trio + PK study).
- **Retatrutide — 2** (Lancet efficacy/safety; BMJ news).
- **Teplizumab — 3**; **Baricitinib — 2**; **zimislecel — 0** in this window.

Publication volume is normal-to-elevated, concentrated in GLP-1/incretin therapies — consistent with ADA 2026 (June) reporting season. [Evidence: SILVER.]

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score, BRONZE — single-source, needs expert confirmation; **note underlying data is from April 20**):

1. **Beta Cell Regen × Health Equity** — 100.0 (0 joint pubs)
2. **Insulin Resistance × Islet Transplant** — 100.0 (1)
3. **Islet Transplant × Drug Repurposing** — 100.0 (0)
4. **Islet Transplant × Health Equity** — 100.0 (0)
5. **Gene Therapy × LADA** — 100.0 (0)

**Tier-1 alignment (per RESEARCH_DOCTRINE §286 — Tier 1 = run computational analysis):** Gaps #3 *Islet Transplant × Drug Repurposing* and #1/#4 *× Health Equity* map onto the hub's existing islet-drug-repurposing network analysis and Trial Equity Mapper assets. These are the strongest candidates for original computational contribution rather than narrative synthesis. The methodologically-distinct pairs (e.g., GWAS × device tech) should stay deprioritized.

---

## Breaking News (web check, last 7 days)

1. **FDA approval — Tzield/teplizumab, pediatric Stage 3 T1D (6/12/2026).** First DMT for recently-diagnosed Stage 3 T1D, ages 8–17. Accelerated approval; confirmatory study ongoing. (See headline.) [GOLD]
2. **Retatrutide Phase 3 — ADA 2026 (New Orleans, 6/6).** First Phase 3 readout for the triple-hormone (GIP/GLP-1/glucagon) agonist; benefits in weight, A1C, plus OSA and knee OA pain. [GOLD — ADA + Lancet]
3. **Novo Nordisk REIMAGINE 1–3 (6/7).** Phase 3 met primary HbA1c and confirmatory weight endpoints. [SILVER — press/secondary]
4. **Oral GLP-1 wave.** Orforglipron (Lancet/JAMA) and a separately reported oral agent (elecoglipron) showing significant glucose + weight effects. [SILVER]

All four corroborate the PubMed therapy clusters above — the literature and trial pipelines are moving in lockstep with ADA 2026.

---

## Recommended Actions

1. **Update tracker + teplizumab trial records** to reflect the 6/12 FDA pediatric Stage-3 approval (label expansion from Stage 2 / adult). Re-tag NCT07088068, NCT05757713, NCT06791291 with the new regulatory status. *(Write action — left for user; this was a review run.)*
2. **Re-run `python project1_literature_gap_analysis.py`** — `literature_gap_data.json` is ~57 days old; the Jun-14 report is built on April data.
3. **Re-run `python baseline_pubmed_alerts.py`** — PubMed snapshot is 4 days stale and we are mid-ADA-2026 reporting season (high churn).
4. **Add to "Notable Trials to Watch"** (currently empty in `clinical_trials_summary.md`): the two Vertex VX-880 Phase 3s, the two Lilly baricitinib Phase 3s, and teplizumab NCT07088068.
5. **Review cross-domain paper [42267680]** (teplizumab response via CGM) — directly relevant to T1D Immunotherapy + the new approval; candidate for the paper library.
6. **Optional computational contribution:** advance the *Islet Transplant × Drug Repurposing* gap (#3) using existing islet-repurposing network assets — a Tier-1 (computational) opportunity per the Doctrine.

---

*Generated by diabetes-hub-monitor (automated). No source files were modified. Evidence levels per RESEARCH_DOCTRINE: GOLD = primary/regulatory, SILVER = secondary/single-analytic, BRONZE = single-source unvalidated.*
